Inclusion Criteria:

- Patients with advanced solid tumors (metastatic or local) unresponsive to standard
therapy, progressed on standard therapy, or no standard therapy exists. No limit to
the number of prior treatment regimens

- Patients may be fully active without physical restrictions, ambulatory with
restrictions on strenuous physical activity, or ambulatory and capable of self-care
but not work activities (i.e., Eastern Cooperative Oncology Group performance status
of greater than or equal to 2)

- Demonstrates adequate organ function (liver, kidneys, hematologic)

Exclusion Criteria:

- Chemotherapy or radiation therapy within 2 weeks of dosing; or unresolved side
effects(s) from prior treatment regimen

- Participation in an investigational study within 14 days of dosing

- Primary central nervous system tumor

- Active brain or spinal cord metastases. Patients who completed a course of therapy
for CNS metastases may be eligible if considered clinically stable for 3 months prior
to study entry

- Symptoms from fluid in the abdomen or around the lungs

- Requires certain drugs or other products known to be metabolized by the liver enzyme
CYP3A4